SCHEMBL4740702

SCHEMBL4740702

O=C1CCCC2CCCC12

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
MT-CO2 P00403 4/20 0.37
ALOX5 P09917 4/20 0.37
KMT2A Q03164 2/20 0.36
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
MAPT P10636 2/20 0.32
HPGD P15428 1/20 0.32
TEK Q02763 1/20 0.32
CREBBP Q92793 1/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL895510 0.95 CA1 (0.42) CA1CA2CA4MT-CO2ALOX5
SCHEMBL22397285 0.95 CA1 (0.42) CA1CA2CA4MT-CO2ALOX5
SCHEMBL11955 0.95 CA1 (0.42) CA1CA2CA4MT-CO2ALOX5
SCHEMBL12333841 0.95 CA1 (0.42) CA1CA2CA4MT-CO2ALOX5
SCHEMBL120444 0.95 CA1 (0.42) CA1CA2CA4MT-CO2ALOX5
SCHEMBL9695672 0.92 CA1 (0.46) CA1CA2CA4MT-CO2ALOX5
SCHEMBL31276198 0.92 KMT2A (0.44) CA1CA2CA4MT-CO2ALOX5
SCHEMBL29107476 0.92 CA1 (0.46) CA1CA2CA4MT-CO2ALOX5
SCHEMBL8902053 0.92 KMT2A (0.44) CA1CA2CA4MT-CO2ALOX5
SCHEMBL3728524 0.92 KMT2A (0.44) CA1CA2CA4MT-CO2ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371642-B2 Benefit agent containing delivery particle THE PROCTER & GAMBLE COMPANY (US) 2025-07-29 US disclosed
US-20230313084-A1 BENEFIT AGENT CONTAINING DELIVERY PARTICLE PROCTER & GAMBLE (US) 2023-10-05 US disclosed
US-11713437-B2 Benefit agent containing delivery particle slurries THE PROCTER & GAMBLE COMPANY (US) 2023-08-01 US disclosed
US-11708546-B2 Benefit agent containing delivery particle THE PROCTER & GAMBLE COMPANY (US) 2023-07-25 US disclosed
US-11334695-B2 Antiperspirant and deodorant compositions comprising malodor reduction compositions THE PROCTER & GAMBLE COMPANY (US) 2022-05-17 US disclosed
US-11334694-B2 Personal care compositions comprising malodor reduction compositions THE PROCTER & GAMBLE COMPANY (US) 2022-05-17 US disclosed
WO-2021162115-A1 LAMINATE, DISPLAY DEVICE, AND ORGANIC ELECTROLUMINESCENCE DISPLAY DEVICE 富士フイルム株式会社 2021-08-19 WO disclosed
US-20210026199-A1 COLORANT FILTER, BACKLIGHT UNIT, AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2021-01-28 US disclosed
US-10806683-B2 Encapsulated perfume compositions GIVAUDAN SA (CH) 2020-10-20 US disclosed
US-10792384-B2 Rolled fibrous structures comprising encapsulated malodor reduction compositions THE PROCTER & GAMBLE COMPANY (US) 2020-10-06 US disclosed
WO-2012100423-A1 ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS ELI LILLY AND COMPANY (US) 2012-08-02 WO disclosed
WO-2008089093-A2 EFFICIENT PROCESSES FOR PREPARING STEROIDS AND VITAMIN D DERIVATIVES WITH THE UNNATURAL CONFIGURATION AT C20 (20 ALPHA-METHYL) FROM PREGNENOLONE QUATRX PHARMACEUTICALS COMPANY (US) 2008-07-24 WO disclosed
US-20080171728-A1 Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone QUATRX PHARMACEUTICALS CO. 2008-07-17 US disclosed
US-20070135394-A1 Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-06-14 US disclosed
EP-1737468-A2 TREATMENT OF INTERSTITIAL CYSTITIS WITH VITAMIN D COMPOUNDS Bioxell S.p.a. (IT) 2007-01-03 EP disclosed
CN-1798721-A Cyclohexyl derivatives as selective estrogen receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2006-07-05 CN disclosed
WO-2005082375-A2 TREATMENT OF INTERSTITIAL CYSTITIS WITH VITAMIN D COMPOUNDS BIOXELL SPA (IT) 2005-09-09 WO disclosed
US-5641784-A ADENOSINE ANTAGONISTS; TREATMENT OF NERVOUS SYSTEM DISORDERS, ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM KG (DE) 1997-06-24 US disclosed
EP-0349204-A2 Use and regeneration of reagents using coupled reactions and permselective barriers BEND RESEARCH, INC. (US) 1990-01-03 EP disclosed
US-4510321-A Autoxidative cleavage of ketones in the presence of pulverized alkali metal hydroxide ALLIED CORPORATION (US) 1985-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171728-A1 Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone CYP2R1, CYP24A1, VDR CA1 4295/4885CA2 4407/4885CA4 3748/4885
US-20070135394-A1 Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds CYP24A1, CYP2R1, VDR CA1 751/4885CA2 933/4885CA4 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.